Introduction
============

Gynecomastia is the benign glandular proliferation of male breast tissue which accounts for 60% of all disorders of male breast[@B1]. It can be unilateral or bilateral, symmetrical or asymmetrical, and painless or tender mass from the acute nonspecific stretching of tissues[@B1],[@B2]. Physiologic gynecomastia can appear bilaterally or unilaterally[@B3] and age specific incidence rates are high in the neonatal period, early to midpuberty, and old age. An estimated 60%-90% of neonates have transient gynecomastia, which can occur due to placental transfer of estrogens from mother to child[@B4]. It is known to disappear spontaneously within 4 weeks of age. Pubertal gynecomastia results from the imbalance between estrogens and androgens within the breast tissue and occurs in as many as 70% of adolescent boys. Seventy-five percent of pubertal gynecomastia resolves within 1-3 years of onset without treatment[@B1]. Among 50- to 80-year-old men, decreased production of testosterone and increased peripheral conversion of androgens to estrogen especially in adipose tissue results in gynecomastia which increases with aging[@B5].

Prepubertal gynecomastia is characterized by the presence of palpable unilateral or bilateral breast tissue in boys without other signs of sexual maturation[@B6]. The prepubertal gynecomastia is not well known and there are only a few case reports in the literature. Because it is generally thought to be pathological, idiopathic prepubertal gynecomastia is a diagnosis of exclusion and a careful history, meticulous physical examination, and pertinent laboratory studies should be performed to exclude the possible pathologic causes[@B7]. We here report the two cases of unilateral gynecomastia in prepubertal boys without other specific symptoms or signs.

Case reports
============

Case 1
------

A 9.6-year-old boy visited outpatient clinic with right nipple tenderness for 2 months. Drugs or dermal applications containing herb materials or estrogens were not used for at least 3 months before visit except for the 5 days of antihistamine drug for allergic rhinitis. There was no acceleration of growth velocity recently and he had no symptoms of galactorrhea. Developmental milestone and school achievement was normal. Family history of breast malignancies or gynecomastia was denied. Generally he was not so ill-looking and his height, weight, and the body mass index (BMI) were 135.6 cm (50th-75th percentile), 37.5 kg (75th-90th percentile), and 20.4 kg/m^2^ (75th-85th percentile), respectively. Tanner stage 2 of right breast sized 1.5 cm × 1.5 cm was palpable with tenderness. There was no redness or local heatness on the right breast and the color change or pigmentation of the right nipple was not found. The left breast showed normal, Tanner stage 1, on inspection and palpation. Testis was palpable symmetrically and their volume was 2 mL for each. Phallus and pubic hair were Tanner stage 1 and genital ambiguity was not found. His thyroid and liver function was normal and serum levels of gonadotropin and sex steroids were within normal range. The serum levels of insulin like growth factor-1 (IGF-1) was 203 ng/mL (25th-50th percentile) and insulin like growth factor binding protein-3 (IGFBP-3) was 4.16 ng/mL (90th-97th percentile) ([Table 1](#T1){ref-type="table"}). Bone age revealed as 11 years. Ultrasound image of breast showed prominent breast tissue in the right without cysts or signs of malignancy and normal in the left ([Fig. 1](#F1){ref-type="fig"}). Ultrasound images of testis and adrenal glands showed normal.

After 3 months of visit, the right breast regressed with only tiny palpable mass left without tenderness. And he was still in prepuberty.

Case 2
------

A 8.8-year-old boy visited outpatient clinic with left breast enlargement for several weeks. He complained of pain and tenderness of his left breast at the start, but symptoms improved after few days. Antipyretics were used about a week ago for 3 days because of upper respiratory infection and no other drugs or dermal applications containing estrogenic materials for at least 3 months before visit were used. There was no acceleration of growth velocity recently and he had no symptoms of galactorrhea. Developmental milestone and school achievement was normal. There was no family history of breast malignancies or gynecomastia. Generally he was not so ill-looking and his height, weight, and the BMI were 129 cm (25th-50th percentile), 22.5 kg (5th percentile), and 13.5 kg/m^2^ (\<3rd percentile), respectively. There was a noticeable asymmetry of breasts with Tanner stage 2 of the left, sized 2.0 cm × 1.5 cm with mild tenderness on palpation. There was no redness or local heatness on the left breast and the color change or pigmentation of the left nipple was not found. The right breast showed normal, Tanner stage 1 on inspection and palpation. Testis was palpable symmetrically and their volume was 2 mL for each. Phallus and pubic hair were Tanner stage 1 and genital ambiguity was not found. His thyroid and liver function was normal and serum levels of gonadotropin and sex steroids were within normal range. The serum levels of IGF-1 was 112 ng/mL (3rd-10th percentile) and IGFBP-3 was 3.40 ng/mL (90th-97th percentile) ([Table 1](#T1){ref-type="table"}). Bone age revealed as 7 years. Ultrasound image of breast showed normal in the right and prominent breast tissue in the left ([Fig. 2](#F2){ref-type="fig"}). Ultrasound images of testis and adrenal glands showed normal.

After 3 months of visit, the size of palpable mass on the left breast showed no interval change. However, pain and tenderness was completely disappeared. And he was still in prepuberty.

Discussion
==========

According to a study of Israel, prepubertal gynecomastia was diagnosed in 29 out of 581 boys (5%) with gynecomastia[@B6]. Their mean age at diagnosis was 8.9±2.2 years which was consistent with our cases. In a report of 20 Korean boys with gynecomastia, younger than 15 years of age, only 2 boys were prepubertal[@B8]. Although it is a rare condition, a finding of breast enlargement in a prepubertal boy requires an extensive medical evaluation and clinical follow-up of the pubertal development in order to rule out endocrinopathies, such as hyperaromatase syndrome, and neoplasms that produce estrogen or human chorionic gonadotropin[@B9]. Hormonal aberrations that cause pathological gynecomastia include absolute or relative estrogen excess resulting from exogenous administration, endogenous overproduction, increased peripheral conversion of androgens to estrogens, androgen deficiency, or androgen insensitivity[@B10].

The absolute or relative androgen deficiency related pathologic gynecomastia can be seen with any form of inherited or acquired hypogonadism[@B2]. The most common chromosomal disorder associated with hypergonadotropic hypogonadism is Klinefelter syndrome[@B2]. The reported prevalence of gynecomastia in Klinefelter syndrome is said around 40%[@B11]. Aromatase excess syndrome (AES) is associated with increased peripheral aromatization of androgens to estrogens and shows similar manifestations to those of Sertoli cell or feminizing adrenocortical tumors[@B12]. AES is a rare entity characterized by accelerated early linear growth, prepubertal gynecomastia, and testicular failure in men[@B13]. Stratakis et al.[@B13] described AES as a cause of the unusual entity of familial gynecomastia. Increased estrogen production and aromatase expression in Sertoli cell tumors associated with Peutz-Jeghers syndrome also can cause prepubertal gynecomastia[@B14]. Gynecomastia is reported as the rare presenting symptom in patients with nonclassic type of 21-hydroxylase deficiency which is thought to be the result of peripheral aromatization of accumulated androgens[@B15]. Hyperthyroidism increases aromatization of androgens to estrogens and decreases free testosterone levels by increasing circulating sex hormone binding globulin levels which results in gynecomastia[@B2].

There are some debates but generalized obesity seems to be associated with the gynecomastia through increased aromatase activity in adipose tissue[@B16]. According to the report, 9 of 29 prepubertal gynecomastia boys (31%) were obese[@B6]. The use of alcohol and illicit drugs, such as marijuana, heroin, methadone, and amphetamines is considered as possible cause of gynecomastia. It is hard to testify but the exposure to environmental chemicals[@B17], which have estrogen like effects, might also be involved in the pathogenesis of gynecomastia. Several herbal supplements, particularly those containing phytoestrogen and estrogen containing hair cream cause prepubertal gynecomastia and other numerous medications[@B18] are summarized in [Table 2](#T2){ref-type="table"}.

Though there are many pathologic causes as described above, a specific cause is rarely identified and over 90% of patients with prepubertal gynecomastia are revealed as idiopathic. Idiopathic and pathologic gynecomastia cannot be distinguished by the initial breast manifestation. Both idiopathic and AES have no accompanied symptoms except for the breast enlargement. But hormonal profiles and bone age may help in the discrimination. Einav-Bachar et al.[@B5] reported the hormonal levels of patients with idiopathic prepubertal gynecomastia were normal and within the prepubertal range, while two patients with AES showed increased estradiol and estrone levels. And usually, both boys and girls with the AES have greatly advanced bone age[@B13].

We did not perform all laboratory tests to rule out various pathologic causes. But glandular proliferation of their breast did not seem to progress and hormonal abnormalities were not found. And other symptoms suggesting pathologic gynecomastia were not revealed. Because both were within normal weight, obesity related increased aromatase activity was excluded. Case 1 demonstrated accelerated bone age compared to his chronologic age. But when considering that the predicted adult height lied within the target range, bone age acceleration is not likely to be pathologic. Additionally none of our cases were exposed to any medications of exogenous agents associated with gynecomastia. All things taken together, therefore, our cases would be benign and idiopathic.

We report two rare cases of prepubertal unilateral gynecomastia, which seem to be idiopathic. They are expected to progress as a benign course but further follow-up to see their pubertal progression and to check other labs such as chromosome study if needed should be performed.
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![The ultrasound images of case 1 showed a hypoechoic and solid lesion (arrows) without signs of malignancy in the retroareolar area of the right breast (A) and normal in the left breast (B).](apem-19-159-g001){#F1}

![The ultrasound images of case 2 showed a hypoechoic and solid lesion (arrows) with irregular margins in the retroareolar area of the left breast (A) and normal in the right breast (B).](apem-19-159-g002){#F2}

###### 

Laboratory results of cases

![](apem-19-159-i001)

TSH, thyroid-stimulating hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; IGF-1, insulin like growth factor-1; IGFBP-3, insulin like growth factor binding protein-3; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

###### 

Drugs associated with gynecomastia

![](apem-19-159-i002)

hCG, human chorionic gonadotropin; GRH, gonadotropin releasing hormone; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; TCA, tricyclic antidepressants; HIV, human immunodeficiency virus.

^a)^Denotes stronger association.
